Our work contributes with valuable insights to the ongoing efforts in identifying robust and clinically relevant biomarkers for MS, emphasizing the nuanced nature of the disease and the potential utility of OPN as additional discriminating factor for diagnosis. The gene discussed is SPP1; the disease is myeloid sarcoma.